Clinical Trial Update: Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS [Phase 2]

View source ↗

Summary

This Phase 2 study reports results on how BG00012 (dimethyl fumarate) affects MRI lesions and pharmacokinetics in pediatric subjects with relapsing-remitting mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BG00012 (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED | Results posted: 2017-04-28